DDA platform, the division of Creative Bioarray which is especially for drug discovery research, is dedicated to providing integrated drug discovery services to pharma, biotechnology companies, and academic institutions around the world. With highly experienced and specialized team in pharmacology, DDA platform utilizes the best screening equipment and cell models, as well as the latest innovations in drug discovery to deliver first-class results. Recently, DDA platform announced the release of its in vitro metabolic stability services to help researchers understand the metabolic profile of various compounds to accelerate drug discovery research.

ADME findings in early development provide a valuable indicator of whether a compound has favorable bioavailability, helping to avoid costly clinical phase failures when drug candidates do not meet ADME profiles or show early signs of toxicity. Creative Bioarray provides comprehensive in vitro ADME services to drug discovery organizations, and many in vitro ADME assays are available in multiple formats to suit different stages of the drug discovery pipeline. While Creative Bioarray has standard procedures for each assay, experienced research teams can also help design custom optimal strategies and protocols to meet any drug discovery need.

Creative Bioarray now offers a wide range of biological systems to determine in vitro metabolic stability, including primary hepatocytes, tissue homogenates, and tissue fractions (e.g., microsomes, mitochondrial preparations, S9 fractions, and intestinal fluids) from various preclinical species. Screening for metabolic stability in microsomes is based on measuring the disappearance of the parent compound. Potential species-dependent metabolic differences can also be detected by using liver microsomes from different animal species and humans.

Metabolic stability services provided by Creative Bioarray are primarily used for LC/MS method development of analytical test articles, and screening is currently available at four selectable time points (short-term, mid-term, long-term course options). And, Creative Bioarray supports incubation with appropriate cofactors in appropriate test systems (S9, microsomes, hepatocytes, recombinant CYP enzymes), triplicate evaluations were performed at multiple time points with additional replicates for key samples for time and cofactor blank comparisons. In addition, Creative Bioarray cultured labeled substrate as a positive control to check the metabolic capacity of the test system for further data analysis.

“Creative Bioarray has a leading portfolio of compound stability services designed to help you understand the metabolic profile of your compounds. All our tests can be ordered individually or in combination.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “Our well-trained and experienced scientific team provides clients with extensive and in-depth expertise in appropriate study design, study execution and data interpretation. We also offer extensive drug metabolism and pharmacokinetic capabilities for new chemical entities and compounds under development.”

About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerate drug development and improve research quality for worldwide projects.